头孢克洛缓释片递减方案治疗再发性尿路感染的研究

目的观察头孢克洛缓释片递减方案治疗再发性尿路感染(RUTI)的效果及不良反应。方法将某院60例RUTI患者按来诊顺序分为治疗组和对照组,各30例,治疗组用头孢克洛缓释片递减方案治疗,对照组用左氧氟沙星片递减方案治疗,观察两组治疗方案临床疗效和不良反应情况。结果治疗组临床治愈24例(80.00%),对照组临床治愈16例(53.33%),治疗组临床治愈率高于对照组,与对照组比较差异有统计学意义(χ2=4.80,P=0.028)。治疗组发生RUTI 2例(6.67%),对照组发生RUTI 8例(26.67%),治疗组再发率低于对照组,差异有统计学意义(χ2=4.32,P=0.038)。治疗组不良反应发生率为16.67%,低于对照组的50.00%,差异有统计学意义(χ2=7.50,P=0.006)。结论头孢克洛缓释片递减方案治疗RUTI疗效好、再发率低、不良反应少,可用于防止RUTI再发的治疗。

Research on diminishing scheme of cefaclor sustained release tablets in the treatment of recurrent urinary tract infection

ObjectiveTo explore the efficacy and adverse reactions of diminishing scheme of cefaclor sustained release tablets in the treatment of recurrent urinary tract infection(RUTI). Methods60  RUTI patients in a hospital were divided into treatment group(n=30) and control group (n=30), patients in treatment group were treated with diminishing scheme of cefaclor sustained release tablets, patients in control group were treated with diminishing scheme of levofloxacin tablets, clinical therapeutic efficacy and adverse reactions of  two groups  were observed. ResultsThe curative rate in treatment group was higher than control group （［80.00%,n=24］vs ［53.33%,n=16］） (χ2=4.80，P=0.028）. The incidence of RUTI in treatment group was lower than control group (［6.67%，n=2］ vs ［26.67%，n=8］)（χ2=4.32，P=0.038）. Incidence of adverse reactions in treatment group was lower than control group (16.67% vs 50.00%)（χ2=7.50，P=0.006）. ConclusionThe diminishing scheme of cefaclor sustained release tablets in the treatment of RUTI has good curative efficacy, low recurrence rate, fewer adverse reactions, and can be used for the treatment of recurrence of RUTI.